Eagle Health Investments LP: ARGENX SE (ARGX): Quarterly 13F Position History
As of Q2 2026, Eagle Health Investments LP reported 76,417 shares of ARGENX SE (ARGX), worth $70.9M and representing 11.8% of its 13F equity book. Quarter-over-quarter share count change: + 81 (+0.1%) . The position first appeared in Q4 2020 and has been disclosed across 23 13F-HR filings in Pactolio's tracked window.
- 76,417Shares Held (Latest Filing)
- $70.9MReported Market Value (Latest Filing)
- 11.8%Portfolio Weight (% of 13F Equity Book)
- +81Quarter-over-Quarter Share Change
- +$15.2MQuarter-over-Quarter Value Change
- 88,890Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 23 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 76,417 | +81 | +0.1% | $70.9M | 11.8% | $927.8 |
| Q1 2026 | 76,336 | +13,606 | +21.7% | $55.7M | 11.7% | $730.3 |
| Q4 2025 | 62,730 | 14,700 | -19.0% | $52.8M | 11.6% | $841.0 |
| Q3 2025 | 77,430 | 0 | – | $57.1M | 15.0% | $737.6 |
| Q2 2025 | 77,430 | +2,440 | +3.3% | $42.7M | 10.5% | $551.2 |
| Q1 2025 | 74,990 | 0 | – | $44.4M | 11.5% | $591.9 |
| Q4 2024 | 74,990 | 0 | – | $46.1M | 11.3% | $615.0 |
| Q3 2024 | 74,990 | 13,900 | -15.6% | $40.7M | 7.8% | $542.1 |
| Q2 2024 | 88,890 | +4,300 | +5.1% | $38.2M | 6.8% | $430.0 |
| Q1 2024 | 84,590 | 0 | – | $33.3M | 6.3% | $393.7 |
| Q4 2023 | 84,590 | +20,190 | +31.4% | $32.2M | 6.5% | $380.4 |
| Q3 2023 | 64,400 | 0 | – | $31.7M | 7.0% | $491.6 |
| Q2 2023 | 64,400 | 0 | – | $25.1M | 4.7% | $389.7 |
| Q1 2023 | 64,400 | +4,100 | +6.8% | $24.0M | 4.7% | $372.6 |
| Q4 2022 | 60,300 | 0 | – | $22.8M | 5.3% | $378.8 |
| Q3 2022 | 60,300 | 0 | – | $21.3M | 4.9% | $353.1 |
| Q2 2022 | 60,300 | 9,600 | -13.7% | $22.8M | 5.3% | $378.9 |
| Q1 2022 | 69,900 | +7,568 | +12.1% | $22.0M | 5.4% | $315.3 |
| Q4 2021 | 62,332 | +8,700 | +16.2% | $21.8M | 5.3% | $350.2 |
| Q3 2021 | 53,632 | +400 | +0.8% | $16.2M | 5.1% | $302.0 |
| Q2 2021 | 53,232 | +10,600 | +24.9% | $16.0M | 5.5% | $301.1 |
| Q1 2021 | 42,632 | +23,045 | +117.7% | $11.7M | 4.8% | $275.4 |
| Q4 2020 | 19,587 | – | – | $5.8M | 3.7% | $294.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Eagle Health Investments LP first disclose a ARGX position in 13F-HR filings?
Eagle Health Investments LP first reported ARGENX SE (ARGX) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 23 reported quarters within Pactolio's tracked window.
What was Eagle Health Investments LP's most recent quarter-over-quarter share-count change in ARGX?
Between Q1 2026 and Q2 2026, Eagle Health Investments LP added 81 shares of ARGX (+0.1%), bringing the total reported position to 76,417 shares at a market value of $70.9M.
Does the implied price-per-share represent Eagle Health Investments LP's cost basis in ARGX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.